Kontaktdaten für Klinische Studien

Für Studienanfragen steht Ihnen unser Dermato-Onkologisches Team zur Verfügung.

Tel.-Nr.: 0621-383-4450 oder 0621-383-3905

e-mail: dermato.onkologie@umm.de

Klinische Studien - mit möglichem Studieneinschluss

- IIT ImmunoPax
 

Immunomonitoring of patients with metastatic melanoma under chemotherapy

- IIT IMMUNED
 

Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

- IIT BOTTOM

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects with Avanced Melanoma

- BMS - CheckMate 401 (CA209401)

Clinical trial of nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line tehrapy of subjects with histologically confirmed stage III (unresecatble) or stage IV melanoma

- BioNTech RNA Pharmaceuticals - Lipo-MERIT
 
Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting Four Tumour-associated Antigens in Patients With Advanced Melanoma

- EORTC 18081
 
Adjuvant pegylated - interferon-alpha2b (SylatronTM) for 2 years vs. observation in patients with a ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group

- EORTC 1208 - Minitub

Prospective registry of sentinel node (SN) positive melanoma patients with minimal SN tumor burden who undergo completion lymph node dissection (CLND) or nodal observation

- Novartis - COMBI-r

Eine nicht-interventionelle Studie bei Patienten mit fortgeschrittenem Melanom zur Bewertung der Kombinationstherapie mit Dabrafenib und Trametinib in der klinischen Routine

Klinische Studien - aktuell kein Studieneinschluss mehr möglich

EORTC 1325    

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma:A ranomized, double-blind phase 3 trial of the EORTC Melanoma Group

Novartis - COLUMBUS
 

A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Roche GO27826
 
A Phase III, randomized, double blind, placebo-controlled study of vemurafenib  (RO5185426) adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence

ADO - Sentinel Studie
 
Kontrollierte und prospektiv randomisierte Therapiestudie zum Vergleich einer radikalen Lymphadenektomie versus Beobachtung bei Patienten mit malignem Melanom >1,0 mm Tumordicke und positivem Wächter-Lymphknoten

BioNTech RNA Pharmaceuticals - IVAC MUTANOME
 
Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of intra-nodal administration of a personalized vaccination with IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002 vaccine in patients with advanced melanoma

Novartis NEMO
 
A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma

Roche GO28141 co-BRIM
 
A Phase III, double-blind, placebo-controlled study of vemurafenib + placebo versus vemurafenib in combination with GDC-0973 (MEK-inhibitor) in previously untreated BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma

BMS IMAGE

A multi-national, prospective, observational study in patients with unresectable or metastatic melanoma 

BioNTech RNA Pharmaceuticals - MERIT
 
Clinical first-in-human dose escalating study evaluating the safetey and tolerability of intranodal administration of an RNA-based cancer vaccine targeting the tumor-associated antigens NY-ESO-1 and tyrosinase in patients with advanced melanoma.

GSK BRF115532 - COMBI-AD
 
Randomisierte, doppelblinde Phase III-Studie zur Dabrafenib in Kombination mit Trametinib im Vergleich zu zwei Placebos bei der adjuvanten Behandlung des Hochrisiko-Melanoms mit BRAF-V600-Mutation nach chirurgischer Resektion

ROCHE ZESS
 
A prospective safety study of patients with BRAFV600 mutation-positive unresectable or metastatic melanoma treated with vemurafenib.

NYESO1-AS15-MEL-001 (MET)
 
Recombinant His/NY-ESO-1 protein combined with the AS15 immunological Adjuvant System (GSK2241658A)

AB Science AB08026
 
A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit

MSD MK-3475 - 006
 
A multicenter, randomized, controlled, three-arm, phase III study to evaluate the safety and efficacy of two dosing schedules of MK-3475 compared to ipilimumab in patients with advanced melanoma

MSD MK-3475 - 002
 
Randomized, Phase II study of the PD-1 inhibitor MK-3475 versus chemotherapy in patients with advanced melanoma

Roche GO28397 
 
A phase I, open-label, multicenter, 3-period, fixed-sequence study to investigate the effect of vemurafenib on the pharmacokinetics of a single dose of acenocoumarol in patients with BRAFV600 mutation-positive metastatic malignancy

GSK MEK116513 - COMBI-v
 
A Phase III, randomisied, open-label study comparing the combination of the BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, to the BRAF inhibitor venmurafenib in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation positive cutaneous melanoma

GSK PRAME
 
An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with PRAME-positive metastatic melanoma

ROCHE BRAIN-METS
 
An open-label, single-arm phase II, multicenter study to evaluate the efficacy of Vemurafenib in patients with brain metastases.

GSK MEK115306 - COMBI-d

Randomisierte, doppelblinde Studie der Phase III zum Vergleich der Kombination des BRAF-Hemmers Dabrafenib und des MEK-Hemmers Trametinib mit Dabrafenib und Placebo als First-Line-Therapie bei Patienten mit nicht reserzierbarem (Stadium IIIC) oder metastasiertem (Stadium IV) kutanen Melanom mit BRAF-V600E/K-Mutation

GSK MEK114267
 
A phase III randomized, open-label study comparing GSK1121212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma

DeCOG-MM-PAL11
 
The IPI - Multibasket Trial in advanced uveal melanoma: Prospective clinical phase II multibasket study in Melanoma patients with advanced disease

ADO ChemoSensMM
 
Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma

ROCHE MO25515
 
An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma

BMS CA 184-029
 
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: a randomized, double-blind Phase III trial of the EORTC Melanoma Group

GSK Predict
 
Predictive gene signature fore REsponse to recMAGE-A3 in unresecteD metastatIc CuTaneous melanoma Recombinant MAGE-A3 protein (recMAGE-A3) combined with the AS15 immunological Adjuvant System

GSK Derma
 
A double-blind, randomized, placebo-controlled phase III study to assiss the efficacy of recMAGE-A3+AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

BMS CA 184-025
 
a multicenter, open-label, phase II study of Ipilimumab (MDX-010) extended-treatment Monotherapy or follow-up for patients previously enrolled in Ipilimumab (MDX-010) protocols

BMS CA 184-024
 
a multicenter, randomized, double-blind, two-arm, phase III Study in Patients with untreated stage III (unresectable) or IV Melanoma receiving Dacarbazine plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine with placebo

nach oben